Under Construction:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below

      Duodopa Logo
      new loz 1
      new loz 2
      new loz 1 mobile
      new loz 3 mobile
      Duodopa Header

      DUODOPA (levodopa/carbidopa intestinal gel) is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.1

      Levodopa may activate malignant melanoma, so DUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.1

      Some patients may not be suitable for DUODOPA. You are strongly advised to read the Prescribing Information (PI) and Summary of Product Characteristics (SmPC), accessible via the links above, to evaluate patient suitability.

      Videos

      In this video, Dr Jonathan Evans describes his experiences identifying and treating Complex/Advanced PD with DUODOPA in a real-world clinical practice.

      In this video, consultant neurologist Professor Alastair Noyce and PD nurse specialist Caroline Budu discuss how they deliver care for their patients with Parkinson's along the disease and treatment journey.

      Downloadable resource

      This downloadable guide may be used to help you identify which device-aided therapy may be suitable for your patients with Complex/Advanced PD.

       

      PD=Parkinson's disease.

      FAQs

      References

      1. DUODOPA (levodopa/carbidopa intestinal gel) Summary of Product Characteristics.
      DUODOPA PRESCRIBING INFORMATION

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      UK-DUOD-230107. Date of preparation: December 2023.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.